NEW ORLEANS — Researchers had hoped in recent times {that a} protein known as GPRC5D may supply a brand new option to get the immune system to seek out and destroy a number of myeloma cells. Now, the outcomes of a Part 2 examine on a bispecific antibody concentrating on this protein provides affirmation.
The information, introduced Saturday on the annual American Society of Hematology conferences, wowed a crowd of attendees, together with clinicians who started excitedly imagining use the brand new drug in observe.